Ocrevus (ocrelizumab) delayed disability progression and worsening hand function among a large group of people with primary progressive multiple sclerosis (PPMS), including those who were older and had more advanced disease. The data, which come from the Phase 3 ORATORIO-HAND trial (NCT04035005), were presented by Jiwon Oh, MD, a neurologist at the University of Toronto, […]
The post AAN 2026: Ocrevus treatment slows disability in advanced PPMS appeared first on Multiple Sclerosis News Today.
Source: multiplesclerosisnewstoday.com